fda warning about compounded semaglutide Warns Against Using Compounded vs. FDA-approved medications: What's

Companies are competing to offer treatments that provide: Strong weight-loss results Favorable safety profiles Convenient dosing Broad patient appeal Industry Impact Pharmaceutical Companies: The development intensifies competition within the rapidly expanding obesity-treatment market

Semaglutide (Wegovy) carries a list price exceeding $1,300 per month

Because compounded injections are not FDA approved, there is increased variability and risk

For context, semaglutide (Wegovy) tops out around 15% and tirzepatide (Zepbound) around 20.9%

Coverage criteria for these weight loss medications typically include: A body mass index (BMI) of 30 or higher OR a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, diabetes, or high cholesterol